In vitro activity of telavancin against gram-positive clinical isolates recently obtained in Europe.
The in vitro activity of telavancin was tested against 620 gram-positive isolates. For staphylococci, MICs at which 50 and 90% of isolates were inhibited (MIC(50) and MIC(90)) were both 0.25 microg/ml, irrespective of methicillin resistance. MIC(50) and MIC(90) were 0.25 and 0.5 microg/ml for vancomycin-susceptible enterococci and 1 and 2 microg/ml for vancomycin-resistant enterococci, respectively. Streptococcus pneumoniae, group A and B beta-hemolytic streptococci, and viridans streptococci were inhibited by < or =0.12 microg/ml.
Jansen
W T M
WT
University Medical Center Utrecht, Eijkman Winkler Institute for Medical Microbiology, Infectious Diseases and Inflammation, G 04.614, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands. W.T.M.Jansen@umcutrecht.nl
Verel
A
A
Verhoef
J
J
Milatovic
D
D
D000617:Aminoglycosides / Q000494:pharmacology*; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D024901:Drug Resistance, Multiple, Bacterial; D005060:Europe; D006094:Gram-Positive Bacteria / Q000187:drug effects*; D016908:Gram-Positive Bacterial Infections / Q000382:microbiology*; D006801:Humans; D000077427:Lipoglycopeptides; D016106:Methicillin Resistance; D008826:Microbial Sensitivity Tests; D013211:Staphylococcus aureus / Q000187:drug effects; D013292:Streptococcus agalactiae / Q000187:drug effects; D013297:Streptococcus pyogenes / Q000187:drug effects; D020713:Vancomycin Resistance; D034363:Viridans Streptococci / Q000187:drug effects
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D000077427:Lipoglycopeptides; C487637:telavancin